Nektar Therapeutics
XMUN:ITH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nektar Therapeutics
XMUN:ITH
|
US |
|
InZinc Mining Ltd
F:32L
|
CA |
|
C
|
Carnegie Clean Energy Ltd
F:CNM1
|
AU |
|
D
|
DLH Holdings Corp
F:TS8A
|
US |
|
Andrew Peller Ltd
F:ANJ
|
CA |
|
Daiwa Cycle Co Ltd
F:OQ7
|
JP |
|
ValiRx PLC
F:EAJF
|
UK |
|
Bechtle AG
LSE:0DPM
|
DE |
|
U
|
Urogen Pharma Ltd
SWB:UR8
|
IL |
|
Prima Meat Packers Ltd
F:83X
|
JP |
|
C
|
Chongqing Rural Commercial Bank Co Ltd
XMUN:C3B
|
CN |
|
C
|
Chongqing Rural Commercial Bank Co Ltd
F:C3B
|
CN |
Nektar Therapeutics
Nektar Therapeutics is a biotechnology company that develops medicines for cancer, autoimmune disease, and other serious illnesses. It mainly works on drug candidates that change how the immune system responds or how the body handles certain treatments, and it has also been known for drug-delivery technology that helps medicines stay in the body longer or work in a more controlled way. The company makes money in a few ways: it may receive research funding, milestone payments, and royalties from partners that use its technology or co-develop its drugs, and it can also earn future sales revenue if any of its own medicines reach the market. Its main customers are not ordinary consumers; they are pharmaceutical partners, hospitals, doctors, and eventually patients if a therapy is approved. What makes Nektar different is that it sits early in the drug value chain. Instead of selling a broad portfolio of established drugs, it focuses on inventing and testing treatments that larger drug companies may later help develop, license, or commercialize. That makes it a research-driven business built around scientific partnerships and the long approval path of biotech drug development.
Nektar Therapeutics is a biotechnology company that develops medicines for cancer, autoimmune disease, and other serious illnesses. It mainly works on drug candidates that change how the immune system responds or how the body handles certain treatments, and it has also been known for drug-delivery technology that helps medicines stay in the body longer or work in a more controlled way.
The company makes money in a few ways: it may receive research funding, milestone payments, and royalties from partners that use its technology or co-develop its drugs, and it can also earn future sales revenue if any of its own medicines reach the market. Its main customers are not ordinary consumers; they are pharmaceutical partners, hospitals, doctors, and eventually patients if a therapy is approved.
What makes Nektar different is that it sits early in the drug value chain. Instead of selling a broad portfolio of established drugs, it focuses on inventing and testing treatments that larger drug companies may later help develop, license, or commercialize. That makes it a research-driven business built around scientific partnerships and the long approval path of biotech drug development.
Phase III underway: Nektar started the global Phase III ZENITH-AD program for rezpegaldesleukin in atopic dermatitis and finalized a single registrational Phase III study design for alopecia areata, with initiation planned for early 2027.
Late-stage timing: The company still expects first atopic dermatitis Phase III data in mid-2028 and, if positive, a BLA submission in 2029; alopecia areata data are expected in the second half of 2029.
Market thesis: Management emphasized that REZPEG’s novel mechanism, durable response, and dosing convenience could differentiate it from IL-13 drugs in atopic dermatitis and from JAK inhibitors in alopecia areata.
Financial strength: Nektar ended the quarter with $1.02 billion in cash and investments and said its runway extends into the third quarter of 2028, after recently raising about $350 million in net proceeds.
2026 guidance: The company kept full-year revenue guidance at $40 million to $45 million, while raising year-end cash guidance to $815 million to $840 million.
Key catalyst: Management highlighted upcoming off-treatment data from the alopecia areata study in the fourth quarter and additional atopic dermatitis durability data next year as important inputs for maintenance dosing decisions.
